PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Reddy, Vivek Y.
TI  - LEADLESS II
DP  - 2015 Dec 09
TA  - MD Conference Express
PG  - 7--8
VI  - 15
IP  - 28 suppl 2
4099  - http://mdc.sagepub.com/content/15/28_suppl_2/7.short
4100  - http://mdc.sagepub.com/content/15/28_suppl_2/7.full
AB  - In the LEADLESS II trial, a leadless cardiac pacemaker was demonstrated to be safe and effective. At 6 months, the serious device-related adverse events occurred in 5.7% of patients, and the primary efficacy end point of acceptable pacing capture threshold and therapeutically acceptable sensing amplitude was achieved in 90% of patients.